ENCLAI Daily · Article of the day 03 Oct 2026 · ENCLAI Editorial

Felzartamab plus lenalidomide-dexamethasone extends progression-free survival in relapsed or refractory multiple myeloma

Randomised trial289 · Lancet Haematology · 1 Oct 2026 · PubMed 42822478

Primary endpointProgression-free survival

191Felzartamab plus lenalidomide-dexamethasone
vs
98Lenalidomide-dexamethasone
Hazard ratio · 95% confidence interval
0.40.60.81.01.2Hazard ratiodark blue = 95% confidence interval (p=0.0035)square = the estimate1 · no difference95% CIexcludes 10.620.450.860.40.60.81.01.2Hazard ratiodark blue = 95% confidence interval (p=0.0035)square = the estimate1 · no difference95% CIexcludes 10.620.450.86
Statistically significant at 95%The 95% confidence interval does not include no difference (1) · p=0.0035
Every number here is copied from the published abstract; nothing is estimated. Verify against the paper before use.
Where these numbers come from
“The full analysis set included 289 patients (191 in the felzartamab plus lenalidomide-dexamethasone group and 98 in the lenalidomide-dexamethasone group).”
“At a median follow-up of 34.5 months (IQR 16.8-40.2) in the felzartamab plus lenalidomide-dexamethasone group and 28.7 months (10.8-38.8) in the lenalidomide-dexamethasone group, median progression-free survival was 18.9 months (95% CI 13.6-24.0) with felzartamab plus lenalidomide-dexamethasone versus 10.4 months (5.8-13.9) with lenalidomide-dexamethasone (hazard ratio 0.62 [95% CI 0.45-0.86]; p=0.0035).”
Customise it in Visual Studio
Infographic — study at a glance
What the authors report
Evidence and source
Infographic — study at a glance

The publication

In a phase 3 trial of Chinese patients with relapsed or refractory multiple myeloma, adding felzartamab to lenalidomide-dexamethasone significantly prolonged progression-free survival compared with lenalidomide-dexamethasone alone. Median progression-free survival was 18.9 months (95% CI 13.6-24.0) with the combination versus 10.4 months (5.8-13.9) with the control regimen (hazard ratio 0.62 [95% CI 0.45-0.86]; p=0.0035).

Who the findings apply to

Adults aged 18 years or older with relapsed or refractory multiple myeloma who had received at least one previous line of systemic therapy and were not refractory to lenalidomide were enrolled.

All 289 patients in the full analysis set were of Asian ethnicity, with 185 (64%) male and 104 (36%) female.

Why this matters

The study evaluated felzartamab, an anti-CD38 monoclonal antibody with attenuated complement-dependent cytotoxicity, to address potential efficacy limitations of CDC-reliant CD38 antibodies in this population. The significant improvement in progression-free survival supports the combination as a potential new treatment option for Chinese patients with relapsed or refractory multiple myeloma.

What the study found

At a median follow-up of 34.5 months (IQR 16.8-40.2) in the felzartamab plus lenalidomide-dexamethasone group and 28.7 months (10.8-38.8) in the lenalidomide-dexamethasone group, median progression-free survival was 18.9 months (95% CI 13.6-24.0) with felzartamab plus lenalidomide-dexamethasone versus 10.4 months (5.8-13.9) with lenalidomide-dexamethasone (hazard ratio 0.62 [95% CI 0.45-0.86]; p=0.0035).

The most common grade 3-4 adverse events in the felzartamab group were neutropenia (105 [55%] of 192), lymphopenia (79 [41%]), leukopenia (74 [39%]), thrombocytopenia (49 [26%]), and pneumonia (44 [23%]).

Treatment-related deaths occurred in 11 (6%) of 192 patients in the felzartamab group and two (2%) of 97 patients in the lenalidomide-dexamethasone group.

What the result does not establish

The trial was conducted exclusively in Chinese patients, all of whom were of Asian ethnicity, limiting generalizability to other populations.

The study was open-label, which may introduce bias in outcome assessment despite independent review committee evaluation.

Higher rates of grade 3-4 neutropenia, lymphopenia, leukopenia, thrombocytopenia, and pneumonia were observed in the felzartamab group compared with the control group.

Authors’ conclusion

“Felzartamab plus lenalidomide-dexamethasone significantly prolonged progression-free survival compared with lenalidomide-dexamethasone alone, supporting felzartamab plus lenalidomide-dexamethasone as a potential new treatment option for Chinese patients with relapsed or refractory multiple myeloma.”

Trial registration

NCT03952091

Registered titleTJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Registry statusPhase 3, interventional, completed
Lead sponsorTJ Biopharma Co., Ltd.
Registered size289 participants — actual enrolment. The abstract reports: 289 patients
Where41 sites in 2 countries (China, Taiwan)
Registered primary outcome
  • Progression-free survival (PFS) (time frame: 18.4 months(Active) 30.7 months(experimental))

Primary endpoint named in the abstract: progression-free survival, defined as the time from randomisation to disease progression or death from any cause,…. Compare the two: a change of primary endpoint after registration matters.

  • Start: Mar 2019
  • Completion: Jun 2024
  • Primary completion: Jun 2024
  • Paper published: Oct 2026
Filled circle: date reached. Open circle: date the registry lists as estimated.

ClinicalTrials.gov record as held by ENCLAI, last updated Jul 2024. The registry status may have changed since; the link shows the current record.

Study and sources

Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial

Randomised trial · Phase 3 · Lancet Haematology · 2026-10-01

Sources and limitations

Share this briefing
ENCLAI tracks outbreaks like this live, from official sources worldwide. Start 7-day free trial  ·  Request a demo →

Follow ENCLAI News

Get new briefings in your news reader. No ENCLAI account needed.

The daily disease brief

One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.

Double opt-in — we send a confirmation link and nothing else until you click it. One-click unsubscribe on every email. See our privacy notice.